# A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy

> **NCT01720563** · PHASE2 · TERMINATED · sponsor: **PhytoHealth Corporation** · enrollment: 17 (actual)

## Conditions studied

- Cancer-related Fatigue

## Interventions

- **DRUG:** Astragalus polysaccharides 500 mg
- **DRUG:** Placebo
- **PROCEDURE:** Concurrent chemoradiotherapy with PUL (cisplatin/tegafur plus uracil (UFT)/leucovorin) every 2 weeks

## Key facts

- **NCT ID:** NCT01720563
- **Lead sponsor:** PhytoHealth Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-12
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Change study drug dosage form
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01720563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01720563, "A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01720563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*